H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on Personalis (PSNL) to $8.50 from $9 and keeps a Buy rating on the shares post the Q2 report. The firm says the biopharma translational research delays lead to the lower guidance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSNL:
- Personalis: Strong Molecular Testing Growth and Strategic MRD Focus Support Buy Rating
- Personalis Reports Q2 2025 Financial Results
- Personalis: Buy Rating Amidst Challenges and Opportunities in MRD Growth
- Personalis reports Q2 EPS (23c), consensus (24c)
- Personalis sees Q3 revenue $12M-$14M, consensus $18.9M